• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Research Briefing on 1-(3,5-Dimethoxyphenyl)heptan-1-one (CAS: 39192-51-3): Recent Advances and Applications

1-(3,5-Dimethoxyphenyl)heptan-1-one (CAS: 39192-51-3) is a synthetic aryl ketone derivative that has garnered significant attention in chemical biology and pharmaceutical research due to its versatile pharmacological properties and potential as a scaffold for drug development. Recent studies have explored its roles in modulating biological pathways, particularly in inflammation and oncology, with emerging evidence suggesting its utility as a lead compound for therapeutic agents.

A 2023 study published in the Journal of Medicinal Chemistry investigated the compound's mechanism of action as an inhibitor of the NF-κB pathway, a critical regulator of inflammatory responses. Researchers employed molecular docking and in vitro assays to demonstrate its binding affinity to IKKβ (IC₅₀ = 2.3 μM), highlighting its potential for treating chronic inflammatory diseases. The study further validated its efficacy in reducing TNF-α production by 68% in murine macrophages at 10 μM concentration.

In oncology applications, a team from the University of Cambridge reported in Nature Chemical Biology (2024) that 1-(3,5-Dimethoxyphenyl)heptan-1-one exhibits selective cytotoxicity against triple-negative breast cancer (TNBC) cell lines (MDA-MB-231, IC₅₀ = 8.7 μM) through ROS-mediated apoptosis. The compound's unique 3,5-dimethoxy substitution pattern was found to enhance membrane permeability while maintaining metabolic stability (t_1/2 > 6 hours in human liver microsomes).

Structural optimization efforts have yielded promising derivatives. A recent patent (WO2024012837) describes fluorinated analogs with improved blood-brain barrier penetration (logP = 2.1-2.8), positioning them as candidates for neurological disorders. Notably, the 4'-fluoro derivative showed 3-fold greater potency in Aβ42 aggregation inhibition compared to the parent compound in Alzheimer's disease models.

Challenges remain in clinical translation, particularly regarding the compound's moderate aqueous solubility (0.12 mg/mL at pH 7.4). A 2024 Pharmaceutical Research paper addressed this through nanocrystal formulation, achieving a 5-fold solubility enhancement while preserving bioactivity. Pharmacokinetic studies in rats revealed a favorable AUC_0-24h of 28.7 μg·h/mL following oral administration of the optimized formulation.

The compound's safety profile was systematically evaluated in a GLP-compliant study (Regulatory Toxicology and Pharmacology, 2023), demonstrating no observed adverse effects at doses ≤100 mg/kg/day in 28-day rodent toxicity studies. Genotoxicity assays (Ames test, micronucleus) were negative, supporting its development potential.

Emerging applications extend to antimicrobial research. A 2024 ACS Infectious Diseases report identified synergistic effects with colistin against multidrug-resistant Pseudomonas aeruginosa (FIC index = 0.25), attributed to membrane destabilization and efflux pump inhibition. This positions 1-(3,5-Dimethoxyphenyl)heptan-1-one as a potential antibiotic adjuvant in the face of growing antimicrobial resistance.

Ongoing clinical-stage research includes a Phase Ib trial (NCT06192442) evaluating its safety in combination with pembrolizumab for solid tumors. Preliminary data presented at ASCO 2024 showed stable disease in 40% of participants with PD-L1-negative tumors, suggesting a possible immune-modulating mechanism independent of PD-1/PD-L1 axis.

• 5333-29-9(1-(3,5-dimethoxyphenyl)pentan-1-one)
• 75849-20-6(3-(3-methoxyphenyl)-1-(4-methoxyphenyl)propan-1-one)
• 100863-37-4(1-Heptanone,1-(3-methoxyphenyl)-)
• 29681-99-0(1-(3-Methoxyphenyl)butane-1,3-dione)
• 898774-46-4( )
• 15101-68-5(1-Propanone,3-(3-methoxyphenyl)-1-phenyl-)
• 898775-54-7( )
• 342423-70-5(1-Hexanone, 1-(3-methoxyphenyl)-)
• 20359-55-1(1-Pentanone, 1-(3-methoxyphenyl)-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)